TY - JOUR
T1 - Critical role for IL-1β in DNA damageinduced mucositis
AU - Kanarek, Naama
AU - Grivennikov, Sergei I.
AU - Leshets, Michael
AU - Lasry, Audrey
AU - Alkalay, Irit
AU - Horwitz, Elad
AU - Shaul, Yoav D.
AU - Stachler, Matthew
AU - Voronov, Elena
AU - Apte, Ron N.
AU - Pagano, Michele
AU - Pikarsky, Eli
AU - Karin, Michael
AU - Ghosh, Sankar
AU - Ben-Neriah, Yinon
PY - 2014/2/11
Y1 - 2014/2/11
N2 - β-TrCP, the substrate recognition subunit of SCF-type ubiquitin ligases, is ubiquitously expressed from two distinct paralogs, targeting for degradation many regulatory proteins, among which is the NF-κB inhibitor IκB. To appreciate tissue-specific roles of β-TrCP, we studied the consequences of inducible ablation of three or all four alleles of the E3 in the mouse gut. The ablation resulted in mucositis, a destructive gut mucosal inflammation, which is a common complication of different cancer therapies and represents a major obstacle to successful chemoradiation therapy. We identified epithelial-derived IL-1β as the culprit of mucositis onset, inducing mucosal barrier breach. Surprisingly, epithelial IL-1β is induced by DNA damage via an NF-κB-independent mechanism. Tissue damage caused by gut barrier disruption is exacerbated in the absence of NF-κB, with failure to express the endogenous IL-1β receptor antagonist IL-1Ra upon fourallele loss. Antibody neutralization of IL-1β prevents epithelial tight junction dysfunction and alleviates mucositis in β-TrCP-deficient mice. IL-1β antagonists should thus be considered for prevention and treatment of severe morbidity associated with mucositis.
AB - β-TrCP, the substrate recognition subunit of SCF-type ubiquitin ligases, is ubiquitously expressed from two distinct paralogs, targeting for degradation many regulatory proteins, among which is the NF-κB inhibitor IκB. To appreciate tissue-specific roles of β-TrCP, we studied the consequences of inducible ablation of three or all four alleles of the E3 in the mouse gut. The ablation resulted in mucositis, a destructive gut mucosal inflammation, which is a common complication of different cancer therapies and represents a major obstacle to successful chemoradiation therapy. We identified epithelial-derived IL-1β as the culprit of mucositis onset, inducing mucosal barrier breach. Surprisingly, epithelial IL-1β is induced by DNA damage via an NF-κB-independent mechanism. Tissue damage caused by gut barrier disruption is exacerbated in the absence of NF-κB, with failure to express the endogenous IL-1β receptor antagonist IL-1Ra upon fourallele loss. Antibody neutralization of IL-1β prevents epithelial tight junction dysfunction and alleviates mucositis in β-TrCP-deficient mice. IL-1β antagonists should thus be considered for prevention and treatment of severe morbidity associated with mucositis.
KW - Anakinra
KW - Anti-IL-1 preventive therapy
KW - Cytotoxic side effects
KW - Graft-vs.-host disease
KW - Gut immunity
UR - http://www.scopus.com/inward/record.url?scp=84893862941&partnerID=8YFLogxK
U2 - 10.1073/pnas.1322691111
DO - 10.1073/pnas.1322691111
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24469832
AN - SCOPUS:84893862941
SN - 0027-8424
VL - 111
SP - E702-E711
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 6
ER -